Premium
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
Author(s) -
Spriano F.,
Tarantelli C.,
Golino G.,
Gaudio E.,
Scalise L.,
Cascione L.,
Zucca E.,
Van Berkel P.,
Stathis A.,
Zammarchi F.,
Bertoni F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.134_2630
Subject(s) - antibody drug conjugate , mtt assay , medicine , pharmacology , conjugate , cell growth , ic50 , cell culture , antibody , cancer research , in vitro , microbiology and biotechnology , immunology , chemistry , biology , monoclonal antibody , biochemistry , genetics , mathematical analysis , mathematics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom